Nuvation Bio Inc. (NUVB-WT)
USD 0.16
(0.65%)
USD 0.16
(0.65%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -99.82 Million USD | 16.63% |
| 2022 | -119.73 Million USD | -28.31% |
| 2021 | -93.31 Million USD | -114.27% |
| 2020 | -43.55 Million USD | -35.68% |
| 2019 | -32.09 Million USD | -3135.79% |
| 2018 | -992 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -20.19 Million USD | 3.03% |
| 2024 Q2 | -45.31 Million USD | -124.34% |
| 2023 Q2 | -26.13 Million USD | 1.47% |
| 2023 Q1 | -26.52 Million USD | -8.98% |
| 2023 FY | -99.82 Million USD | 16.63% |
| 2023 Q3 | -26.33 Million USD | -0.8% |
| 2023 Q4 | -20.83 Million USD | 20.91% |
| 2022 Q4 | -24.33 Million USD | 17.05% |
| 2022 Q3 | -29.33 Million USD | 22.53% |
| 2022 Q2 | -37.87 Million USD | -34.33% |
| 2022 Q1 | -28.19 Million USD | 4.79% |
| 2022 FY | -119.73 Million USD | -28.31% |
| 2021 Q4 | -29.6 Million USD | -29.92% |
| 2021 FY | -93.31 Million USD | -114.27% |
| 2021 Q1 | -20.48 Million USD | -48.78% |
| 2021 Q3 | -22.79 Million USD | -11.53% |
| 2021 Q2 | -20.43 Million USD | 0.24% |
| 2020 Q2 | -9.01 Million USD | 2.2% |
| 2020 FY | -43.55 Million USD | -35.68% |
| 2020 Q4 | -13.76 Million USD | -19.24% |
| 2020 Q3 | -11.54 Million USD | -28.05% |
| 2020 Q1 | -9.22 Million USD | 13.19% |
| 2019 Q2 | -8 Million USD | 0.0% |
| 2019 Q4 | -10.62 Million USD | -93.99% |
| 2019 Q3 | -5.47 Million USD | 31.58% |
| 2019 FY | -32.09 Million USD | -3135.79% |
| 2019 Q1 | -8 Million USD | 0.0% |
| 2018 FY | -992 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ADC Therapeutics SA | -165.98 Million USD | 39.861% |
| Alto Neuroscience, Inc. | -37.8 Million USD | -164.017% |
| Annovis Bio, Inc. | -45.03 Million USD | -121.654% |
| Biohaven Pharmaceutical Holding Company Ltd. | -436.05 Million USD | 77.108% |
| Ginkgo Bioworks Holdings, Inc. | -864.4 Million USD | 88.452% |
| Nuvation Bio Inc. | -99.82 Million USD | -0.0% |
| Arcus Biosciences, Inc. | -340 Million USD | 70.641% |
| Theriva Biologics, Inc. | -21.43 Million USD | -365.783% |
| Zymeworks Inc. | -138.05 Million USD | 27.693% |